S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
Log in
NASDAQ:AMED

Amedisys Competitors

$235.18
+3.88 (+1.68 %)
(As of 11/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$231.45
Now: $235.18
$238.54
50-Day Range
$231.30
MA: $249.66
$268.56
52-Week Range
$132.95
Now: $235.18
$273.77
Volume109,364 shs
Average Volume268,782 shs
Market Capitalization$7.72 billion
P/E Ratio47.13
Dividend YieldN/A
Beta0.9

Competitors

Amedisys (NASDAQ:AMED) Vs. LH, DGX, DVA, CHE, LHCG, and AMN

Should you be buying AMED stock or one of its competitors? Companies in the sub-industry of "health care services" are considered alternatives and competitors to Amedisys, including Laboratory Co. of America (LH), Quest Diagnostics (DGX), DaVita (DVA), Chemed (CHE), LHC Group (LHCG), and AMN Healthcare Services (AMN).

Amedisys (NASDAQ:AMED) and Laboratory Co. of America (NYSE:LH) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

Profitability

This table compares Amedisys and Laboratory Co. of America's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amedisys8.22%26.41%12.43%
Laboratory Co. of America6.79%21.05%8.83%

Institutional & Insider Ownership

79.8% of Amedisys shares are owned by institutional investors. Comparatively, 88.7% of Laboratory Co. of America shares are owned by institutional investors. 2.8% of Amedisys shares are owned by insiders. Comparatively, 0.7% of Laboratory Co. of America shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

Amedisys has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500. Comparatively, Laboratory Co. of America has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500.

Valuation and Earnings

This table compares Amedisys and Laboratory Co. of America's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amedisys$1.96 billion3.95$126.83 million$4.4053.45
Laboratory Co. of America$11.55 billion1.66$823.80 million$11.3217.36

Laboratory Co. of America has higher revenue and earnings than Amedisys. Laboratory Co. of America is trading at a lower price-to-earnings ratio than Amedisys, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Amedisys and Laboratory Co. of America, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amedisys031002.77
Laboratory Co. of America011502.94

Amedisys currently has a consensus target price of $252.3846, indicating a potential upside of 7.32%. Laboratory Co. of America has a consensus target price of $225.1875, indicating a potential upside of 14.62%. Given Laboratory Co. of America's stronger consensus rating and higher probable upside, analysts clearly believe Laboratory Co. of America is more favorable than Amedisys.

Summary

Laboratory Co. of America beats Amedisys on 8 of the 14 factors compared between the two stocks.

Amedisys (NASDAQ:AMED) and Quest Diagnostics (NYSE:DGX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, earnings, institutional ownership and valuation.

Analyst Ratings

This is a breakdown of recent ratings for Amedisys and Quest Diagnostics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amedisys031002.77
Quest Diagnostics09802.47

Amedisys currently has a consensus target price of $252.3846, indicating a potential upside of 7.32%. Quest Diagnostics has a consensus target price of $126.6471, indicating a potential upside of 1.86%. Given Amedisys' stronger consensus rating and higher possible upside, research analysts clearly believe Amedisys is more favorable than Quest Diagnostics.

Profitability

This table compares Amedisys and Quest Diagnostics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amedisys8.22%26.41%12.43%
Quest Diagnostics13.22%19.23%8.77%

Earnings & Valuation

This table compares Amedisys and Quest Diagnostics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amedisys$1.96 billion3.95$126.83 million$4.4053.45
Quest Diagnostics$7.73 billion2.17$858 million$6.5618.95

Quest Diagnostics has higher revenue and earnings than Amedisys. Quest Diagnostics is trading at a lower price-to-earnings ratio than Amedisys, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

79.8% of Amedisys shares are owned by institutional investors. Comparatively, 78.9% of Quest Diagnostics shares are owned by institutional investors. 2.8% of Amedisys shares are owned by company insiders. Comparatively, 1.5% of Quest Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Risk and Volatility

Amedisys has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500. Comparatively, Quest Diagnostics has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500.

Summary

Amedisys beats Quest Diagnostics on 9 of the 14 factors compared between the two stocks.

DaVita (NYSE:DVA) and Amedisys (NASDAQ:AMED) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, valuation, dividends and profitability.

Profitability

This table compares DaVita and Amedisys' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
DaVita7.32%43.99%5.27%
Amedisys8.22%26.41%12.43%

Volatility and Risk

DaVita has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500. Comparatively, Amedisys has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500.

Insider and Institutional Ownership

95.3% of DaVita shares are owned by institutional investors. Comparatively, 79.8% of Amedisys shares are owned by institutional investors. 1.0% of DaVita shares are owned by insiders. Comparatively, 2.8% of Amedisys shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares DaVita and Amedisys' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DaVita$11.39 billion1.08$810.98 million$5.4020.30
Amedisys$1.96 billion3.95$126.83 million$4.4053.45

DaVita has higher revenue and earnings than Amedisys. DaVita is trading at a lower price-to-earnings ratio than Amedisys, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations for DaVita and Amedisys, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
DaVita04202.33
Amedisys031002.77

DaVita currently has a consensus target price of $77.50, indicating a potential downside of 29.29%. Amedisys has a consensus target price of $252.3846, indicating a potential upside of 7.32%. Given Amedisys' stronger consensus rating and higher probable upside, analysts clearly believe Amedisys is more favorable than DaVita.

Summary

Amedisys beats DaVita on 8 of the 14 factors compared between the two stocks.

Amedisys (NASDAQ:AMED) and Chemed (NYSE:CHE) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends and earnings.

Insider and Institutional Ownership

79.8% of Amedisys shares are owned by institutional investors. Comparatively, 83.2% of Chemed shares are owned by institutional investors. 2.8% of Amedisys shares are owned by company insiders. Comparatively, 4.0% of Chemed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Amedisys and Chemed's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amedisys$1.96 billion3.95$126.83 million$4.4053.45
Chemed$1.94 billion3.88$219.92 million$13.9533.83

Chemed has lower revenue, but higher earnings than Amedisys. Chemed is trading at a lower price-to-earnings ratio than Amedisys, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Amedisys has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. Comparatively, Chemed has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500.

Profitability

This table compares Amedisys and Chemed's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amedisys8.22%26.41%12.43%
Chemed13.11%38.13%21.70%

Analyst Recommendations

This is a summary of recent recommendations and price targets for Amedisys and Chemed, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amedisys031002.77
Chemed00203.00

Amedisys presently has a consensus price target of $252.3846, indicating a potential upside of 7.32%. Chemed has a consensus price target of $535.00, indicating a potential upside of 13.36%. Given Chemed's stronger consensus rating and higher possible upside, analysts clearly believe Chemed is more favorable than Amedisys.

Summary

Chemed beats Amedisys on 9 of the 14 factors compared between the two stocks.

LHC Group (NASDAQ:LHCG) and Amedisys (NASDAQ:AMED) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, analyst recommendations and risk.

Profitability

This table compares LHC Group and Amedisys' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
LHC Group5.00%9.78%6.67%
Amedisys8.22%26.41%12.43%

Institutional and Insider Ownership

79.8% of Amedisys shares are owned by institutional investors. 4.8% of LHC Group shares are owned by insiders. Comparatively, 2.8% of Amedisys shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Volatility & Risk

LHC Group has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500. Comparatively, Amedisys has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500.

Valuation and Earnings

This table compares LHC Group and Amedisys' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LHC Group$2.08 billion2.99$95.73 million$4.4744.03
Amedisys$1.96 billion3.95$126.83 million$4.4053.45

Amedisys has lower revenue, but higher earnings than LHC Group. LHC Group is trading at a lower price-to-earnings ratio than Amedisys, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and target prices for LHC Group and Amedisys, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
LHC Group02602.75
Amedisys031002.77

LHC Group presently has a consensus target price of $198.75, indicating a potential upside of 0.98%. Amedisys has a consensus target price of $252.3846, indicating a potential upside of 7.32%. Given Amedisys' stronger consensus rating and higher possible upside, analysts plainly believe Amedisys is more favorable than LHC Group.

Summary

Amedisys beats LHC Group on 10 of the 14 factors compared between the two stocks.

AMN Healthcare Services (NYSE:AMN) and Amedisys (NASDAQ:AMED) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, valuation, analyst recommendations, risk and institutional ownership.

Volatility & Risk

AMN Healthcare Services has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Comparatively, Amedisys has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500.

Valuation and Earnings

This table compares AMN Healthcare Services and Amedisys' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AMN Healthcare Services$2.22 billion1.41$113.99 million$3.1820.89
Amedisys$1.96 billion3.95$126.83 million$4.4053.45

Amedisys has lower revenue, but higher earnings than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Amedisys, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

91.1% of AMN Healthcare Services shares are owned by institutional investors. Comparatively, 79.8% of Amedisys shares are owned by institutional investors. 1.4% of AMN Healthcare Services shares are owned by insiders. Comparatively, 2.8% of Amedisys shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current recommendations and price targets for AMN Healthcare Services and Amedisys, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AMN Healthcare Services00713.13
Amedisys031002.77

AMN Healthcare Services currently has a consensus target price of $70.8571, suggesting a potential upside of 6.65%. Amedisys has a consensus target price of $252.3846, suggesting a potential upside of 7.32%. Given Amedisys' higher probable upside, analysts clearly believe Amedisys is more favorable than AMN Healthcare Services.

Profitability

This table compares AMN Healthcare Services and Amedisys' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AMN Healthcare Services3.78%20.38%6.87%
Amedisys8.22%26.41%12.43%

Summary

Amedisys beats AMN Healthcare Services on 11 of the 15 factors compared between the two stocks.


Amedisys Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Laboratory Co. of America logo
LH
Laboratory Co. of America
1.4$196.46+1.2%$19.14 billion$11.55 billion22.87
Quest Diagnostics logo
DGX
Quest Diagnostics
1.8$124.33+1.3%$16.76 billion$7.73 billion15.37Insider Selling
DaVita logo
DVA
DaVita
1.8$109.60+0.1%$12.28 billion$11.39 billion16.43
Chemed logo
CHE
Chemed
2.2$471.95+1.8%$7.53 billion$1.94 billion28.62Analyst Upgrade
LHC Group logo
LHCG
LHC Group
1.2$196.83+0.2%$6.22 billion$2.08 billion59.83
AMN Healthcare Services logo
AMN
AMN Healthcare Services
1.2$66.44+0.8%$3.12 billion$2.22 billion35.53
R1 RCM logo
RCM
R1 RCM
1.3$20.21+1.0%$2.36 billion$1.19 billion202.12
The Providence Service logo
PRSC
The Providence Service
1.0$135.51+1.5%$1.92 billion$1.51 billion-2,258.12
MEDNAX logo
MD
MEDNAX
1.4$20.36+1.1%$1.74 billion$3.51 billion-0.87
CorVel logo
CRVL
CorVel
0.8$92.23+1.2%$1.65 billion$592.22 million40.99Insider Selling
Tivity Health logo
TVTY
Tivity Health
1.6$17.53+0.5%$852.31 million$1.13 billion-1.77Analyst Upgrade
Cross Country Healthcare logo
CCRN
Cross Country Healthcare
1.4$9.32+4.0%$350.09 million$822.22 million-17.92Analyst Upgrade
Interpace Biosciences logo
IDXG
Interpace Biosciences
1.7$3.19+5.0%$12.89 million$24.08 million-0.38Upcoming Earnings
Heavy News Reporting
This page was last updated on 11/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.